Wen is among the 40 finalists heading to Washington D.C. Thursday to present their projects to panels of experts. The winners ...
Zacks Investment Research on MSN3h
Why Is Regeneron (REGN) Down 4.1% Since Last Earnings Report?It has been about a month since the last earnings report for Regeneron (REGN). Shares have lost about 4.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...
Shares of Regeneron Pharmaceuticals Inc. REGN rose 1.73% to $687.15 Wednesday, on what proved to be an all-around favorable ...
In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Regeneron (REGN – Research Report), with a price target of ...
Regeneron Pharmaceuticals has received a positive opinion from the European Medicines Agency’s human medicines committee for ...
We recently published a list of 10 Worst Performing Large Cap Stocks to Buy According to Analysts. In this article, we are ...
NEW YORK CITY, NY / ACCESS Newswire / March 5, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results ...
Regeneron’s gene therapy, dubbed DB-OTO, is a cell-selective AAV gene therapy for children with hearing loss stemming from a ...
In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other worst performing large cap stocks to buy according to analysts. How Did The ...
This was the stock's fifth consecutive day of losses.
Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback